Olaparib for the treatment of epithelial ovarian cancer

References

• GLOBOCAN: Estimated cancer incidence, mortality and prevalence worldwide in 2012. [Internet]. 2012 [cited 2015 May 26]. Available from: http://globocan.iacr.fr/Pages/fact_sheets_population.aspx
   Google Scholar
• Perren TJ, Swart AM, Pfisterer J, et al. ICON 7 - A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–2496.
   PubMed Web of Science ®Google Scholar
• Burger R, Brady MF, Bookman M, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–2483.
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Blank S, Goff BA, et al. OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039–2045.
   PubMed Web of Science ®Google Scholar
• Kaufman B, Shapira-Frommer R, Schmutzler R, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015;33(3):244–250.
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–921.
   PubMed Web of Science ®Google Scholar
• Ashworth A. A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol. 2008;26(22):3785–3790.
   PubMed Web of Science ®Google Scholar
• Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian cancer study group. J Clin Oncol. 2012;30(21):2654–2663.
   PubMed Web of Science ®Google Scholar
• Bell D, Berchuck A, Birrer M, et al. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–615.
   PubMed Web of Science ®Google Scholar
• Menear KA, Adcock C, Boulter R, et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem. 2008;51(20):6581–6591.
   PubMed Web of Science ®Google Scholar
• Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913–917.
   PubMed Web of Science ®Google Scholar
• Hay T, Matthews JR, Pietzka L, et al. Poly(ADP-Ribose) polymerase-1 inhibitor treatment regresses autochthonous brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin. Cancer Res. 2009;69(9):3850–3855.
   PubMed Web of Science ®Google Scholar
• Evers B, Drost R, Schut E, et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res. 2008;14(12):3916–3925.
   PubMed Web of Science ®Google Scholar
• Rottenberg S, Jaspers JE, Kersbergen A, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A. 2008;105(44):17079–17084.
   PubMed Web of Science ®Google Scholar
• Fong P, Boss D, Yap T, et al. Inhibition of poly(ADP-Ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123–134.
   PubMed Web of Science ®Google Scholar
• Plummer R, Swaisland H, Leunen K, et al. Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours. Cancer Chemother Pharmacol. 2015;76(4):723–729.
   PubMed Web of Science ®Google Scholar
• Molife L, Forster M, Krebs M, et al. A phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors. J Clin Oncol. 2010;28(15s):Suppl;abstr 2599.
   PubMed Web of Science ®Google Scholar
• Rolfo C, Swaisland H, Leunen K, et al. Effect of food on the pharmacokinetics of olaparib after oral dosing of the capsule formulation in patients with advanced solid tumors. Adv Ther. 2015;32(6):510–522.
   PubMed Web of Science ®Google Scholar
• AstraZeneca. Prescribing information for olaparib. 2014.
   Google Scholar
• Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010;28(15):2512–2519.
   PubMed Web of Science ®Google Scholar
• Mateo J, Friedlander M, Sessa C, et al. Administration of continuous/intermittent olaparib in ovarian cancer patients with a germline BRCA1/2 mutation to determine an optimal dosing schedule for the tablet formulation. Eur J Cancer. 2013;49(Suppl2):Abstr801.
   Google Scholar
• Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial. Lancet. 2010;376(9737):245–251.
   PubMed Web of Science ®Google Scholar
• Kim G, Ison G, McKee AE, et al. FDA approval summary: Olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin Cancer Res. 2015;21(19):4257–4262.
   PubMed Web of Science ®Google Scholar
• Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12(9):852–861.
   PubMed Web of Science ®Google Scholar
• Kaye S, Lubinski J, Matulonis U, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-Ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol. 2012;30(4):372–379.
   PubMed Web of Science ®Google Scholar
• Safra T, Borgato L, Nicoletto MO, et al. BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin. Mol Cancer Ther. 2011;10(10):2000–2007.
   PubMed Web of Science ®Google Scholar
• Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. New Engl J Med. 2012;366:1382–1392.
   PubMed Web of Science ®Google Scholar
• Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852–861.
   PubMed Web of Science ®Google Scholar
• Oza A, Cibula D, Benzaquen A, et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 2015;16(1):87–97.
   PubMed Web of Science ®Google Scholar
• Liu J, Barry W, Mirrer M, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014;15(11):1207–1214.
   PubMed Web of Science ®Google Scholar
• Dong J, Zhang T, Wen B. Impact of olaparib for maintenance monotherapy on survival in breast and ovarian cancer : a systematic review and pooled analysis of published trials. Int J Med Physics, Clin Eng Radiat Oncol. 2015;4:338–347.
   Google Scholar
• Banerjee S, Ledermann J, Matulonis U, et al. Management of nausea and vomiting during treatment with the capsule (CAP) and tablet (TAB) formulations of the PARP inhibitor olaparib. Eur J Cancer. 2015;51(Suppl 3):S550.
   PubMed Web of Science ®Google Scholar
• Genetic/Familial High-risk Assessment: Breast and Ovarian. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) [Internet]. 2015 [cited 2015 Dec 13]. Available from: www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf
   Google Scholar
• Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764–775.
   PubMed Web of Science ®Google Scholar
• McNeish I, Oza A, Coleman R, et al. Results of ARIEL2: A Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis. J Clin Oncol. 2015;33:Abstr 5508.
   Google Scholar
• Smith H, Walters Haygood C, Arend R, et al. PARP inhibitors as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: Acost-effectiveness analysis. Gynecol Oncol. 2015;139:59–62.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Kaye SB, Ashworth A. Making the best of PARP inhibitors in ovarian cancer. Nat Rev Clin Oncol. 2010;7(9):508–519.
   PubMed Web of Science ®Google Scholar